The zeitgeist of resistance

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue SUPPL. 1, 2007, Pages

  Livermore, David ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Epidemiology of resistance; Extended spectrum lactamase; MRSA; Quinolone resistance; Vancomycin resistant Staphylococcus aureus

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; UNITED KINGDOM;

BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; GREAT BRITAIN; HUMANS;

EID: 34948900917     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm160     Document Type: Article

References (32)

1. UK Standing Medical Advisory Committee (SMAC). The Path of Least Resistance, Department of Health, London, 1998.
2. Health Protection Agency, London 2006. Mandatory Surveillance of Healthcare Associated Infections Report 2006. www.hpa.org.uk/ infections/topics_az/hai/mandatory_report_2006.htm. (1 March 2007, date last accessed).
3. Smith JT. Frequency and expression of mutational resistance to the 4-quinolone antibacterials. Scand J Infect Dis Suppl 1986; 49: 115-23.
4. Livermore DM, James D, Reacher M et al. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 2002; 8: 473-8.
5. Lillie MB, Livermore DM, Pearson A et al. Incidence of bacteremia due to ciprofloxacin- and cephalosporin-resistant Escherichia coli reported in England, 2001 to 2005. In: Abstracts of the Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2006. Abstract C2-107, p. 103. American Society for Microbiology, Washington, DC, USA.
6. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
7. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213-6.
8. Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 2006; 42: 37-45.
9. Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
10. Hyle EP, Lipworth AD, Zaoutis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extendedspectrum β-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 1375-80.
11. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
12. Woodford N, Dallow JW, Hill RL et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-9.
13. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the United Kingdom and in-vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
14. Coelho JM, Turton JF, Kaufmann ME et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-7.
15. Echols RM, Heyd A, O'Keeffe BJ et al. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex Transm Dis 1994; 21: 345-52.
16. Fenton KA, Ison C, Johnson AP et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003; 361: 1867-9.
17. Health Protection Agency, London 2006. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme 2005. www.hpa.org.uk/infections/topics_az/hiv_and_sti/stigonorrhoea/ publications/GRASP_2005_Annual_Report.pdf (1 March 2007, date last accessed).
18. Ison CA, Mouton JW, Jones K et al. Which cephalosporin for gonorrhoea? Sex Transm Infect 2004; 80: 386-8.
19. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
20. Gemmell CG. Glycopeptide resistance in Staphylococcus aureus: is it a real threat? J Infect Chemother 2004; 10: 69-75.
21. Ross JE, Fritsche TR, Sader HS et al. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvoxw Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents 2007; 29: 295-301.
22. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-20.
23. Martin IM, Ison CA, Aanensen DM et al. Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis 2005; 192: 1191-5.
24. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extendedspectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
25. Johnson AP, Aucken HM, Cavendish S et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001; 48: 143-4.
26. Klugman KP. The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 50 Suppl S2: 1-5.
27. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-64.
28. Dunman PM, Murphy E, Haney S et al. Transcription profilingbased identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 2001; 183: 7341-53.
29. Papakyriacou H, Vaz D, Simor A et al. Molecular analysis of the accessory gene regulator (agr) locus and balance of virulence factor expression in epidemic methicillin-resistant Staphylococcus aureus. J Infect Dis 2000; 181: 990-1000.
30. Baraniak A, Fiett J, Sulikowska A et al. Countrywide spread of CTX-M-3 extended-spectrum β-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2002; 46: 151-9.
31. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I et al. Bacterial programmed cell death and multicellular behavior in bacteria. PLoS Genet 2006; 2: e135.
32. Karisik E, Underwood A, Ellington M et al. Complete nucleotide sequence of pEK499, a multi-drug resistance plasmid from the UK's most prevalent Escherichia coli strain with CTX-M-15 β-lactamase. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007. ESCMID.